Clinical Trials Decriminalization Topical Treatment 
Canna Law Blog
NOVEMBER 27, 2021
Medicines and Healthcare Products Regulatory Agency for one of its DMT products for the treatment of major depressive disorder. In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. Compass Pathways Releases Phase 2B Trial Results.
Cannabis Law Report
MAY 29, 2022
Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. Celebrated author Michael Pollan has published two bestselling books on the topic: How to Change Your Mind and This is Your Mind on Plants. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8]
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MAY 19, 2021
While many countries around the world have legalized or decriminalized cannabis or have eased up on enforcement in recent years, in Japan in 2018 there was a sharp increase in cannabis-related arrests — and 80% of them were possession charges. That could potentially change in the near future, however. Shutterstock).
Cannabis Law Report
SEPTEMBER 10, 2019
Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression. Mushrooms as Medicine?
Cannabis Law Report
SEPTEMBER 14, 2021
13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.
Cannabis Law Report
SEPTEMBER 9, 2021
Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Thus, a wide application scope has led to an increased product demand for the treatment of various chronic conditions.
The Blunt Truth
AUGUST 13, 2019
In each instance, the companies were selling products with flagrant disease-related claims that the FDA had not approved for the treatment or prevention of any ailments. 331(ll)), the FDA prohibits the sale of products containing an ingredient that has been treated as a drug or involved in clinical trials, without prior FDA approval.
Expert insights. Personalized for you.
91 
Let's personalize your content